Get the Stockscreener App
108.93
2.16%
2.35
Rhythm Pharmaceuticals Inc stock is traded at $108.93, with a volume of 195.13K.
It is up +2.16% in the last 24 hours and down -1.44% over the past month.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.
See More
Previous Close:
$106.58
Open:
$108.92
24h Volume:
195.13K
Relative Volume:
0.31
Market Cap:
$7.27B
Revenue:
$136.86M
Net Income/Loss:
$-168.69M
P/E Ratio:
-38.77
EPS:
-2.81
Net Cash Flow:
$-113.49M
1W Performance:
+8.33%
1M Performance:
-1.44%
6M Performance:
+74.60%
1Y Performance:
+81.71%
1-Day Range:
$106.69
$109.88
1-Week Range:
$98.52
$109.88
52-Week Range:
$45.91
$116.00
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
Name
Rhythm Pharmaceuticals Inc
Sector
Industry
Phone
857-264-4280
Address
222 BERKELEY STREET, BOSTON, MA
Compare RYTM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RYTM
Rhythm Pharmaceuticals Inc
|
108.95 | 7.11B | 136.86M | -168.69M | -113.49M | -2.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
428.59 | 107.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
782.13 | 80.03B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.11 | 57.37B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
908.09 | 55.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
208.00 | 44.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-10-25 | Initiated | Goldman | Buy |
| Jul-07-25 | Initiated | Leerink Partners | Outperform |
| Apr-07-25 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-05-25 | Resumed | Stifel | Buy |
| Jan-02-25 | Initiated | Jefferies | Buy |
| Dec-20-24 | Initiated | Oppenheimer | Outperform |
| Oct-21-24 | Initiated | Guggenheim | Buy |
| Sep-18-24 | Initiated | H.C. Wainwright | Buy |
| Sep-17-24 | Initiated | JMP Securities | Mkt Outperform |
| May-08-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-01-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-18-23 | Resumed | Canaccord Genuity | Buy |
| Aug-08-22 | Upgrade | Goldman | Neutral → Buy |
| Aug-05-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-17-22 | Reiterated | Needham | Buy |
| Mar-02-22 | Resumed | Stifel | Buy |
| Feb-17-22 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-14-21 | Resumed | Goldman | Neutral |
| Aug-04-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Aug-04-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Nov-30-20 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-08-20 | Initiated | Goldman | Sell |
| Jul-12-19 | Upgrade | Stifel | Hold → Buy |
| Jul-08-19 | Initiated | Canaccord Genuity | Buy |
| Mar-13-19 | Initiated | Ladenburg Thalmann | Buy |
| Sep-07-18 | Resumed | Morgan Stanley | Overweight |
| Jun-25-18 | Reiterated | Needham | Buy |
| Jun-15-18 | Reiterated | Needham | Buy |
| Oct-30-17 | Initiated | BofA/Merrill | Buy |
| Oct-30-17 | Initiated | Needham | Buy |
View All
Rhythm Pharmaceuticals Inc Stock (RYTM) Latest News
Citigroup Initiates Coverage on Rhythm Pharmaceuticals (RYTM) with a Buy Rating | RYTM Stock News - GuruFocus
Rhythm Pharmaceuticals initiated with Buy at Citi on Imcivree's potential - Seeking Alpha
Citigroup Initiates Rhythm Pharmaceuticals at Buy With $136 Price Target - MarketScreener
Will Rhythm Pharmaceuticals Inc. (1RV) stock enhance shareholder valueOil Prices & Fast Exit/Entry Strategy Plans - newser.com
Can Rhythm Pharmaceuticals Inc. stock rebound after recent weakness2025 Big Picture & High Conviction Buy Zone Picks - newser.com
Is Rhythm Pharmaceuticals Inc. (1RV) stock expanding market penetration2025 Top Decliners & Free Low Drawdown Momentum Trade Ideas - newser.com
Why analysts recommend Rhythm Pharmaceuticals Inc. (1RV) stock2025 Performance Recap & Real-Time Buy Signal Notifications - newser.com
Rhythm Pharmaceuticals Ranked 31st on Deloitte Fast 500 List - citybiz
Will Rhythm Pharmaceuticals Inc. (1RV) stock profit from automation waveWeekly Gains Summary & Daily Stock Trend Watchlist - newser.com
Why Rhythm Pharmaceuticals Inc. (1RV) stock is favored by hedge fundsSwing Trade & Weekly Top Performers Watchlists - newser.com
Can Rhythm Pharmaceuticals Inc. stock weather global recessionEarnings Growth Report & High Accuracy Swing Trade Signals - newser.com
Is it time to cut losses on Rhythm Pharmaceuticals Inc.Layoff News & Long-Term Growth Stock Strategies - newser.com
Why retail investors favor Rhythm Pharmaceuticals Inc. stockWeekly Trade Recap & Precise Trade Entry Recommendations - newser.com
Can machine learning forecast Rhythm Pharmaceuticals Inc. recoveryWeekly Investment Recap & Weekly Watchlist of Top Performers - newser.com
Can Rhythm Pharmaceuticals Inc. (1RV) stock hold up in economic slowdownWeekly Gains Report & Free Fast Gain Swing Trade Alerts - newser.com
Is Rhythm Pharmaceuticals Inc. (1RV) stock supported by free cash flow2025 Institutional Moves & Verified Swing Trading Watchlists - newser.com
Rhythm Pharmaceuticals Inc Stock (RYTM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Rhythm Pharmaceuticals Inc Stock (RYTM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Cramer Pamela J. | Chief Human Resources Officer |
Nov 20 '25 |
Sale |
105.00 |
3,350 |
351,750 |
20,814 |
0.42%
1.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):